Recently, lapatinib was shown to suppress HER2 phosphorylation and ubiquitination, resulting in a significant accumulation of inactive HER2 receptors at the cell surface, which enhanced the effect of trastuzumab-induced, antibody-dependent cellular cytotoxicity in HER2-overexpressing breast cancer cells [37]. This evidence concerns the gene ERBB2 and breast cancer.